Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer?

• Verfasst von: Kripp, Melanie [VerfasserIn]
• Verfasst von: Horisberger, Karoline [VerfasserIn]
• Verfasst von: Mai, Sabine [VerfasserIn]
• Verfasst von: Kienle, Peter [VerfasserIn]
• Verfasst von: Gaiser, Timo [VerfasserIn]
• Verfasst von: Post, Stefan [VerfasserIn]
• Verfasst von: Wenz, Frederik [VerfasserIn]
• Verfasst von: Merx, Kirsten [VerfasserIn]
• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Titel: Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer?
• Titelzusatz: long-term results from phase II trials
• Verf.angabe: M. Kripp, K. Horisberger, S. Mai, P. Kienle, T. Gaiser, S. Post, F. Wenz, K. Merx, R.-D. Hofheinz
• Jahr: 2015
• Umfang: 9 S.
• Fussnoten: Gesehen am 31.05.2017
• Titel Quelle: Enthalten in: Gastroenterology research and practice
• Ort Quelle: New York, NY : Hindawi, 2008
• Jahr Quelle: 2015
• Band/Heft Quelle: (2015) Artikel-Nummer e273489, 9 Seiten
• ISSN Quelle: 1687-630X
• DOI: doi:10.1155/2015/273489
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1559189525

Abstract

Purpose. The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC). We report the long-term results in patients treated within two sequential clinical trials. Methods. Patients receiving neoadjuvant RCT using capecitabine and irinotecan (CapIri) within a phase I/II trial or CapIri + cetuximab within a phase II trial were evaluated for analysis of disease-free survival (DFS) and overall survival (OS). KRAS exon 2 mutational status had been analyzed in patients receiving cetuximab. Results. 37 patients from the CapIri trial and 49 patients from the CapIri-cetuximab treatment group were evaluable. Median follow-up time was 75.2 months. The 5-year DFS rate was 82% (CapIri) and 79% (CapIri-cetuximab) . The median OS was 127.4 months. 5-year OS was 73% for both groups (CapIri and CapIri-cetuximab) . No significant difference in DFS or OS was noticed between patients receiving CapIri and those receiving CapIri-cetuximab with KRAS wild-type tumors. Conclusions. As the addition of cetuximab did not improve neither DFS nor OS it should not play a role in the perioperative treatment of patients with LARC, not even of patients with (K)RAS WT tumors.